TY - JOUR
T1 - Dose-dense chemotherapy for breast cancer
T2 - what does the future hold?
AU - Morris, Patrick G.
AU - McArthur, Heather L.
AU - Hudis, Clifford
AU - Norton, Larry
PY - 2010/6
Y1 - 2010/6
N2 - Within the last several decades adjuvant polychemotherapy for breast cancer has evolved with the development of anthracyclines and taxanes. Parallel to these developments, granulocyte-colony stimulating factor support has permitted the safe delivery of chemotherapy at shorter ('dose-dense') intertreatment intervals, which, as predicted by preclinical models, has further improved survival. Recently, insights into tumor biology have led the development of targeted therapies, such as trastuzumab for HER2-positive disease, and this has now been successfully incorporated into dose-dense therapy. Newer targeted agents may be similarly incorporated into dose-dense regimens to further improve patient outcomes. This article reviews dose-dense therapy and discusses its role as a chemotherapy foundation for additional targeted agents.
AB - Within the last several decades adjuvant polychemotherapy for breast cancer has evolved with the development of anthracyclines and taxanes. Parallel to these developments, granulocyte-colony stimulating factor support has permitted the safe delivery of chemotherapy at shorter ('dose-dense') intertreatment intervals, which, as predicted by preclinical models, has further improved survival. Recently, insights into tumor biology have led the development of targeted therapies, such as trastuzumab for HER2-positive disease, and this has now been successfully incorporated into dose-dense therapy. Newer targeted agents may be similarly incorporated into dose-dense regimens to further improve patient outcomes. This article reviews dose-dense therapy and discusses its role as a chemotherapy foundation for additional targeted agents.
UR - http://www.scopus.com/inward/record.url?scp=77957258083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77957258083&partnerID=8YFLogxK
U2 - 10.2217/fon.10.59
DO - 10.2217/fon.10.59
M3 - Review article
C2 - 20528233
AN - SCOPUS:77957258083
SN - 1479-6694
VL - 6
SP - 951
EP - 965
JO - Future oncology (London, England)
JF - Future oncology (London, England)
IS - 6
ER -